Boston Financial Mangement LLC Acquires 263,314 Shares of Pfizer Inc. (NYSE:PFE)

Boston Financial Mangement LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 33.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,054,464 shares of the biopharmaceutical company's stock after buying an additional 263,314 shares during the quarter. Boston Financial Mangement LLC's holdings in Pfizer were worth $27,975,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Swiss National Bank raised its holdings in Pfizer by 0.6% in the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock worth $486,762,000 after purchasing an additional 100,900 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 11.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after acquiring an additional 12,864,343 shares in the last quarter. Empowered Funds LLC lifted its position in Pfizer by 80.9% during the 3rd quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock valued at $14,709,000 after acquiring an additional 227,349 shares during the period. Addison Advisors LLC boosted its stake in Pfizer by 394.2% during the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock worth $1,512,000 after acquiring an additional 41,668 shares in the last quarter. Finally, KBC Group NV grew its holdings in Pfizer by 26.0% in the third quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock worth $89,872,000 after purchasing an additional 639,985 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent research reports. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Guggenheim reiterated a "buy" rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.42 on Friday, hitting $26.32. 45,181,154 shares of the company's stock were exchanged, compared to its average volume of 38,114,637. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a 50-day simple moving average of $26.28 and a 200-day simple moving average of $27.44. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $149.14 billion, a PE ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.10 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. This is a boost from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio (DPR) is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.